Flavoxate

Summary

Flavoxate (CHEMBL1493) is an approved small-molecule muscarinic antagonist (ATC G04BD02); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BD02
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 391.5 Da · C24H25NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1493
Name	Flavoxate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3354
ChEBI	CHEBI:5088
ATC	G04BD02
Molecular formula	C24H25NO4
Molecular weight	391.5
InChIKey	SPIUTQOUKAMGCX-UHFFFAOYSA-N

SMILES: CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4

IUPAC name: 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate

ChEBI definition: A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.

Pharmacological roles (ChEBI): parasympatholytic, muscarinic antagonist, antispasmodic drug.

Also known as: Bladuril, Flavoxate, Flavoxato, SID11112543, flavoxate, FLAVOXATE, Flavoxate HCl

Parent form; salt/anhydrous children: CHEMBL1200875

Patent coverage: 1,777 distinct patent families (6,472 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,421 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Lysine-specific demethylase 4E, Prelamin-A/C, Alpha-2A adrenergic receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor.

Bioactivity

ChEMBL activities: 16 potent at pChembl ≥ 5 of 23 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	6.05	AC50	880.1	nM	CHEMBL_ACT_25194631
LMNA	5.9	Potency	1259	nM	CHEMBL_ACT_3626197
OPRM1	5.52	AC50	3046	nM	CHEMBL_ACT_25158286
HTR1A	5.51	AC50	3113	nM	CHEMBL_ACT_25165135
CHRM2	5.47	AC50	3394	nM	CHEMBL_ACT_25195847
KCNH2	5.42	AC50	3800	nM	CHEMBL_ACT_25117843
ADORA3	5.28	AC50	5287	nM	CHEMBL_ACT_25198812
PDE4A	5.21	AC50	6124	nM	CHEMBL_ACT_25207198
ADRA1A	5.2	AC50	6288	nM	CHEMBL_ACT_25218944
CYP1A2	5.2	AC50	6310	nM	CHEMBL_ACT_6034271
CYP2D6	5.1	Potency	7943	nM	CHEMBL_ACT_4970014
CYP2D6	5.1	AC50	7943	nM	CHEMBL_ACT_6041657
CHRM1	5.02	AC50	9601	nM	CHEMBL_ACT_25210306
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4993773
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5062604
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6022938

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4).

The 2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00440739	PHASE4	COMPLETED	Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)
NCT00992238	PHASE1	COMPLETED	A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).